260 related articles for article (PubMed ID: 19276080)
1. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors.
Chang DK; Chiu CY; Kuo SY; Lin WC; Lo A; Wang YP; Li PC; Wu HC
J Biol Chem; 2009 May; 284(19):12905-16. PubMed ID: 19276080
[TBL] [Abstract][Full Text] [Related]
2. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
3. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
[TBL] [Abstract][Full Text] [Related]
4. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.
Chang DK; Lin CT; Wu CH; Wu HC
PLoS One; 2009; 4(1):e4171. PubMed ID: 19137069
[TBL] [Abstract][Full Text] [Related]
5. A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFα to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil.
Lu L; Li ZJ; Li LF; Shen J; Zhang L; Li MX; Xiao ZG; Wang JH; Cho CH
Peptides; 2017 Nov; 97():54-63. PubMed ID: 28970092
[TBL] [Abstract][Full Text] [Related]
6. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
7. Vascular targeting with phage peptide libraries.
Pasqualini R
Q J Nucl Med; 1999 Jun; 43(2):159-62. PubMed ID: 10429511
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
9. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.
Shimizu K; Asai T; Fuse C; Sadzuka Y; Sonobe T; Ogino K; Taki T; Tanaka T; Oku N
Int J Pharm; 2005 May; 296(1-2):133-41. PubMed ID: 15885465
[TBL] [Abstract][Full Text] [Related]
10. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.
Asai T; Shimizu K; Kondo M; Kuromi K; Watanabe K; Ogino K; Taki T; Shuto S; Matsuda A; Oku N
FEBS Lett; 2002 Jun; 520(1-3):167-70. PubMed ID: 12044891
[TBL] [Abstract][Full Text] [Related]
11. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
12. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
Gray BP; McGuire MJ; Brown KC
PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
[TBL] [Abstract][Full Text] [Related]
13. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
14. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
[TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin.
Rivera-Fillat MP; Reig F; Martínez EM; Grau-Oliete MR
J Pept Sci; 2010 Jul; 16(7):315-21. PubMed ID: 20552567
[TBL] [Abstract][Full Text] [Related]
17. Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
Oku N; Asai T; Watanabe K; Kuromi K; Nagatsuka M; Kurohane K; Kikkawa H; Ogino K; Tanaka M; Ishikawa D; Tsukada H; Momose M; Nakayama J; Taki T
Oncogene; 2002 Apr; 21(17):2662-9. PubMed ID: 11965539
[TBL] [Abstract][Full Text] [Related]
18. A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity.
Matsuo AL; Juliano MA; Figueiredo CR; Batista WL; Tanaka AS; Travassos LR
Mol Cancer Res; 2011 Nov; 9(11):1471-8. PubMed ID: 21900362
[TBL] [Abstract][Full Text] [Related]
19. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery.
Lee TY; Wu HC; Tseng YL; Lin CT
Cancer Res; 2004 Nov; 64(21):8002-8. PubMed ID: 15520208
[TBL] [Abstract][Full Text] [Related]
20. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.
Yeh CY; Hsiao JK; Wang YP; Lan CH; Wu HC
Biomaterials; 2016 Aug; 99():1-15. PubMed ID: 27209258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
